Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Cited by (117)

Items 101–117 of 117

1. SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease
   Robert C. Stanton · 2021 · Seminars in Nephrology
2. Priorities and practicalities of prescribing diabetes medicines with cardiovascular and renal protective effects: an Australian perspective
   Sarah A. Hitchen, Nick S.R. Lan, P. Gerry Fegan, Bu Beng Yeap · 2020 · Internal Medicine Journal
3. Angiotensinogen and Risk of Stroke Events in Patients with Type 2 Diabetes Mellitus
   Tao Liu, Weihong Liu · 2022 · Diabetes Metabolic Syndrome and Obesity
4. Soluble tumor necrosis factor receptor type 1 predicts cardiorenal outcomes and better associated with distinct cardiovascular or renal outcomes than precedential renal or cardiovascular events in type 2 diabetes mellitus
   Li-Hsin Chang, Chia-Huei Chu, Chin‐Chou Huang, Liang‐Yu Lin · 2023 · Therapeutic Advances in Endocrinology and Metabolism
5. Empagliflozin in combination with trandolapril but not with triple therapy improves glucose and lipid metabolism in non-diabetic hypertensive model
   Silvie Hojná, Hana Malínská, Martina Hüttl, Irena Marková, Zdeňka Vaňourková, Denisa Miklánková, Jaroslav Hrdlička, František Papoušek, Jan Neckář, Michal Behuliak et al. · 2026 · Biomedicine & Pharmacotherapy
6. The Use of Sodium-Glucose Cotransporter-2 Inhibitors in Coronary Revascularization: Where Are We Now? A Systematic Review
   Ryaan EL‐Andari, Nicholas M. Fialka, Jimmy J.H. Kang, Sabin Joseph Bozso, Jayan Nagendran, Jeevan Nagendran · 2023 · American Journal of Cardiovascular Drugs
7. Consenso colombiano basado en evidencia y en la opinión de expertos para la utilización de los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT-2) en el continuo cardiorrenal de pacientes con enfermedad renal crónica
   Juan Diego Montejo-Hernández, John Mauricio Lopera, Carlos Rosselli San Martín, Izkay Ronderos, Rodrigo Daza-Arnedo, Erica Yama-Mosquera, Jhont Alberth Flechas López, R. Guerrero, Kateir Contreras, Elkin Machacón Miranda et al. · 2025 · Revista Colombiana de Nefrología
8. Should the cardio‐protective properties of sodium‐glucose cotransporter 2 inhibitors dictate therapeutic decision‐making in patients with type 2 diabetes
   Tamara Y. Milder, Richard Osborne Day, SOPHIE LENA STOCKER, Jerry Richard Greenfield · 2020 · Internal Medicine Journal
9. What Have We Learned so Far From the Use of Sodium-Glucose Cotransporter 2 Inhibitors in Clinical Practice?
   Peter R Rossing, Frederik Persson · 2021 · Advances in Chronic Kidney Disease
10. Trans-Ethnic Mendelian Randomization Study Reveals Causal Relationships Between Cardiometabolic Factors and Chronic Kidney Disease
    Jie Zheng, Yuemiao Zhang, Humaira Rasheed, Venexia M. Walker, Yuka Sugawara, Jiachen Li, Yue Leng, Benjamin Elsworth, Robyn E. Wootton, Si Fang et al. · 2021 · SSRN Electronic Journal
11. Analyzing human knockouts to validate GPR151 as a therapeutic target for reduction of body mass index
    Allan M. Gurtan, John E. Dominy, Shareef Khalid, Linh Vong, Shari L. Caplan, Treeve Currie, Sean Richards, Lindsey B. Lamarche, Daniel P. Denning, Diana Shpektor et al. · 2021 · medRxiv
12. Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease
    Минара Шамхаловна Шамхалова, Olga Yu. Sukhareva, Marina Vladimirovna Shestakova · 2022 · Terapevticheskii arkhiv
13. ACTING EARLY TO PROTECT RENAL: BEYOND GLYCEMIC CONTROL OF SGLT2 INHIBITORS
    Yulianto Kusnadi · 2022 · Conferences of Medical Sciences Dies Natalis Faculty of Medicine Universitas Sriwijaya
14. Current Practice of Nephrology and New Technologies Supporting It
    Motoko Yanagita · 2023 · Nihon Naika Gakkai Zasshi
15. The Contributions of Risk Factor Modifications to the Reduction of Cardiovascular Risk in Patients With Antidiabetic Treatment: A Meta‐Regression Analysis and Model‐Based Analysis
    Xingyun Zhu, Chu Lin, Zonglin Li, Xiaoling Cai, Fang Lv, Wenjia Yang, Linong Ji · 2025 · Diabetes/Metabolism Research and Reviews
16. Pharmacotherapies in Prevention of Myocardial Oxidative Stress Mediated by Anthracyclines, Taxanes, and Alkylating Agents
    Evans Osuji, Jonathan Lawrence Wright, Tanvi Brar, Shane S. Scott, Sakima Ahmad Smith · 2025 · Oxidative stress in applied basic research and clinical practice
17. Design, rationale, and baseline characteristics of the dapagliflozin in haemodialysis (DAPA-HD) trial
    Thomas A. Zelniker, Christopher Paschen, Christopher Mann, Manfred Eigner, Hildegard Hafner-Gießauf, Josef Kletzmayr, Matthias Lorenz, Bernhard H. Ludvik, Thomas M. Stulnig, Ingmar Waller et al. · 2026 · ESC Heart Failure